Literature DB >> 30204297

Modeling Chronic Graft Versus Host Disease in Mice Using Allogeneic Bone Marrow and Splenocyte Transfer.

Mark A Schroeder1, Kidist Ashami1, Karl Staser2.   

Abstract

This unit describes a method for allogeneic bone marrow and splenocyte transfer for the modeling of chronic graft versus host disease (cGVHD) in mice. Preclinical models provide clinically relevant platforms for mechanistic and therapeutic studies that may inform the treatment of patients suffering from cGVHD, a common and potentially severe complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). Most murine models of cGVHD depend on the transfer of major histocompatibility complex (MHC)-mismatched bone marrow and whole splenocytes (or purified T cells) into an irradiated recipient. The bone marrow contains hematopoietic stem and progenitor cells necessary to reconstitute the irradiated host hematopoietic system, while splenocytes contain T cells that mediate cGVHD. Of note, specific mouse strains, splenocyte dose, bone marrow quantity, and irradiation doses vary widely across different cGVHD models. Here we describe donor bone marrow and splenocyte preparation, recipient irradiation and intravenous injection of donor cells, and clinical monitoring for disease emergence and progression.
© 2018 by John Wiley & Sons, Inc. © 2018 John Wiley & Sons, Inc.

Entities:  

Keywords:  allogeneic hematopoietic stem cell transplantation; disease modeling; graft versus host disease; splenocyte transfer

Mesh:

Year:  2018        PMID: 30204297      PMCID: PMC6249102          DOI: 10.1002/cpph.47

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  16 in total

1.  Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease.

Authors:  James S Young; Tao Wu; Yuhong Chen; Dongchang Zhao; Hongjun Liu; Tangsheng Yi; Heather Johnston; Jeremy Racine; Xiaofan Li; Audrey Wang; Ivan Todorov; Defu Zeng
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

2.  Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.

Authors:  Michael Boyiadzis; Mukta Arora; John P Klein; Anna Hassebroek; Michael Hemmer; Alvaro Urbano-Ispizua; Joseph H Antin; Brian J Bolwell; Jean-Yves Y Cahn; Mitchell S Cairo; Corey S Cutler; Mary E Flowers; Robert P Gale; Roger Herzig; Luis M Isola; David A Jacobsohn; Madan H Jagasia; Thomas R Klumpp; Stephanie J Lee; Effie W Petersdorf; Stella Santarone; Stephen R Spellman; Harry C Schouten; Leo F Verdonck; John R Wingard; Daniel J Weisdorf; Mary M Horowitz; Steven Z Pavletic
Journal:  Clin Cancer Res       Date:  2014-10-27       Impact factor: 12.531

Review 3.  Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets.

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  N Engl J Med       Date:  2017-12-28       Impact factor: 91.245

4.  Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.

Authors:  Jing Du; Katelyn Paz; Ryan Flynn; Ante Vulic; Tara M Robinson; Katie E Lineburg; Kylie A Alexander; Jingjing Meng; Sabita Roy; Angela Panoskaltsis-Mortari; Michael Loschi; Geoffrey R Hill; Jonathan S Serody; Ivan Maillard; David Miklos; John Koreth; Corey S Cutler; Joseph H Antin; Jerome Ritz; Kelli P MacDonald; Timothy W Schacker; Leo Luznik; Bruce R Blazar
Journal:  Blood       Date:  2017-03-02       Impact factor: 22.113

Review 5.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

Review 6.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

7.  Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.

Authors:  Tao Wu; James S Young; Heather Johnston; Xiong Ni; Ruishu Deng; Jeremy Racine; Miao Wang; Audrey Wang; Ivan Todorov; Jianmin Wang; Defu Zeng
Journal:  J Immunol       Date:  2013-05-24       Impact factor: 5.422

8.  Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?

Authors:  Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2016-03-18       Impact factor: 22.113

Review 9.  Mouse models of graft-versus-host disease: advances and limitations.

Authors:  Mark A Schroeder; John F DiPersio
Journal:  Dis Model Mech       Date:  2011-05       Impact factor: 5.758

10.  Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.

Authors:  Steven D Schutt; Jianing Fu; Hung Nguyen; David Bastian; Jessica Heinrichs; Yongxia Wu; Chen Liu; Daniel G McDonald; Joseph Pidala; Xue-Zhong Yu
Journal:  PLoS One       Date:  2015-09-08       Impact factor: 3.240

View more
  1 in total

1.  Treatment with Mesenchymal Stromal Cells Overexpressing Fas-Ligand Ameliorates Acute Graft-versus-Host Disease in Mice.

Authors:  Andrei Mircea Vacaru; Ana-Maria Mazilu; Madalina Dumitrescu; Ioana Madalina Fenyo; Anca Violeta Gafencu; Ana-Maria Vacaru
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.